Clinical study of genomic drivers in pancreatic ductal adenocarcinoma

Michael T. Barrett, Ray Deiotte, Elizabeth Lenkiewicz, Smriti Malasi, Tara Holley, Lisa Evers, Richard G Posner, Timothy Jones, Haiyong Han, Mark Sausen, Victor E. Velculescu, Jeffrey Drebin, Peter O'Dwyer, Gayle Jameson, Ramesh K. Ramanathan, Daniel D. Von Hoff

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Pancreatic ductal adenocarcinoma (PDA) is a lethal cancer with complex genomes and dense fibrotic stroma. This study was designed to identify clinically relevant somatic aberrations in pancreatic cancer genomes of patients with primary and metastatic disease enrolled and treated in two clinical trials.Methods: Tumour nuclei were flow sorted prior to whole genome copy number variant (CNV) analysis. Targeted or whole exome sequencing was performed on most samples. We profiled biopsies from 68 patients enrolled in two Stand Up to Cancer (SU2C)-sponsored clinical trials. These included 38 resected chemoradiation naïve tumours (SU2C 20206-003) and metastases from 30 patients who progressed on prior therapies (SU2C 20206-001). Patient outcomes including progression-free survival (PFS) and overall survival (OS) were observed.Results: We defined: (a) CDKN2A homozygous deletions that included the adjacent MTAP gene, only its' 3′ region, or excluded MTAP; (b) SMAD4 homozygous deletions that included ME2; (c) a pancreas-specific MYC super-enhancer region; (d) DNA repair-deficient genomes; and (e) copy number aberrations present in PDA patients with long-term (≥ 40 months) and short-term (≤ 12 months) survival after surgical resection.Conclusions: We provide a clinically relevant framework for genomic drivers of PDA and for advancing novel treatments.

Original languageEnglish (US)
Pages (from-to)572-582
Number of pages11
JournalBritish Journal of Cancer
Volume117
Issue number4
DOIs
StatePublished - Aug 8 2017

Fingerprint

Adenocarcinoma
Genome
Neoplasms
DNA Repair-Deficiency Disorders
Clinical Trials
Exome
Survival
Pancreatic Neoplasms
Disease-Free Survival
Pancreas
Clinical Studies
Neoplasm Metastasis
Biopsy
Therapeutics
Genes

Keywords

  • CNVs
  • flow sorting
  • focal amplicons
  • homozygous deletions
  • KRAS mutations
  • pancreatic cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Barrett, M. T., Deiotte, R., Lenkiewicz, E., Malasi, S., Holley, T., Evers, L., ... Von Hoff, D. D. (2017). Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. British Journal of Cancer, 117(4), 572-582. https://doi.org/10.1038/bjc.2017.209

Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. / Barrett, Michael T.; Deiotte, Ray; Lenkiewicz, Elizabeth; Malasi, Smriti; Holley, Tara; Evers, Lisa; Posner, Richard G; Jones, Timothy; Han, Haiyong; Sausen, Mark; Velculescu, Victor E.; Drebin, Jeffrey; O'Dwyer, Peter; Jameson, Gayle; Ramanathan, Ramesh K.; Von Hoff, Daniel D.

In: British Journal of Cancer, Vol. 117, No. 4, 08.08.2017, p. 572-582.

Research output: Contribution to journalArticle

Barrett, MT, Deiotte, R, Lenkiewicz, E, Malasi, S, Holley, T, Evers, L, Posner, RG, Jones, T, Han, H, Sausen, M, Velculescu, VE, Drebin, J, O'Dwyer, P, Jameson, G, Ramanathan, RK & Von Hoff, DD 2017, 'Clinical study of genomic drivers in pancreatic ductal adenocarcinoma', British Journal of Cancer, vol. 117, no. 4, pp. 572-582. https://doi.org/10.1038/bjc.2017.209
Barrett MT, Deiotte R, Lenkiewicz E, Malasi S, Holley T, Evers L et al. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. British Journal of Cancer. 2017 Aug 8;117(4):572-582. https://doi.org/10.1038/bjc.2017.209
Barrett, Michael T. ; Deiotte, Ray ; Lenkiewicz, Elizabeth ; Malasi, Smriti ; Holley, Tara ; Evers, Lisa ; Posner, Richard G ; Jones, Timothy ; Han, Haiyong ; Sausen, Mark ; Velculescu, Victor E. ; Drebin, Jeffrey ; O'Dwyer, Peter ; Jameson, Gayle ; Ramanathan, Ramesh K. ; Von Hoff, Daniel D. / Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. In: British Journal of Cancer. 2017 ; Vol. 117, No. 4. pp. 572-582.
@article{bb2ff7679e0947768b46d4641ef6a6ba,
title = "Clinical study of genomic drivers in pancreatic ductal adenocarcinoma",
abstract = "Background: Pancreatic ductal adenocarcinoma (PDA) is a lethal cancer with complex genomes and dense fibrotic stroma. This study was designed to identify clinically relevant somatic aberrations in pancreatic cancer genomes of patients with primary and metastatic disease enrolled and treated in two clinical trials.Methods: Tumour nuclei were flow sorted prior to whole genome copy number variant (CNV) analysis. Targeted or whole exome sequencing was performed on most samples. We profiled biopsies from 68 patients enrolled in two Stand Up to Cancer (SU2C)-sponsored clinical trials. These included 38 resected chemoradiation na{\"i}ve tumours (SU2C 20206-003) and metastases from 30 patients who progressed on prior therapies (SU2C 20206-001). Patient outcomes including progression-free survival (PFS) and overall survival (OS) were observed.Results: We defined: (a) CDKN2A homozygous deletions that included the adjacent MTAP gene, only its' 3′ region, or excluded MTAP; (b) SMAD4 homozygous deletions that included ME2; (c) a pancreas-specific MYC super-enhancer region; (d) DNA repair-deficient genomes; and (e) copy number aberrations present in PDA patients with long-term (≥ 40 months) and short-term (≤ 12 months) survival after surgical resection.Conclusions: We provide a clinically relevant framework for genomic drivers of PDA and for advancing novel treatments.",
keywords = "CNVs, flow sorting, focal amplicons, homozygous deletions, KRAS mutations, pancreatic cancer",
author = "Barrett, {Michael T.} and Ray Deiotte and Elizabeth Lenkiewicz and Smriti Malasi and Tara Holley and Lisa Evers and Posner, {Richard G} and Timothy Jones and Haiyong Han and Mark Sausen and Velculescu, {Victor E.} and Jeffrey Drebin and Peter O'Dwyer and Gayle Jameson and Ramanathan, {Ramesh K.} and {Von Hoff}, {Daniel D.}",
year = "2017",
month = "8",
day = "8",
doi = "10.1038/bjc.2017.209",
language = "English (US)",
volume = "117",
pages = "572--582",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Clinical study of genomic drivers in pancreatic ductal adenocarcinoma

AU - Barrett, Michael T.

AU - Deiotte, Ray

AU - Lenkiewicz, Elizabeth

AU - Malasi, Smriti

AU - Holley, Tara

AU - Evers, Lisa

AU - Posner, Richard G

AU - Jones, Timothy

AU - Han, Haiyong

AU - Sausen, Mark

AU - Velculescu, Victor E.

AU - Drebin, Jeffrey

AU - O'Dwyer, Peter

AU - Jameson, Gayle

AU - Ramanathan, Ramesh K.

AU - Von Hoff, Daniel D.

PY - 2017/8/8

Y1 - 2017/8/8

N2 - Background: Pancreatic ductal adenocarcinoma (PDA) is a lethal cancer with complex genomes and dense fibrotic stroma. This study was designed to identify clinically relevant somatic aberrations in pancreatic cancer genomes of patients with primary and metastatic disease enrolled and treated in two clinical trials.Methods: Tumour nuclei were flow sorted prior to whole genome copy number variant (CNV) analysis. Targeted or whole exome sequencing was performed on most samples. We profiled biopsies from 68 patients enrolled in two Stand Up to Cancer (SU2C)-sponsored clinical trials. These included 38 resected chemoradiation naïve tumours (SU2C 20206-003) and metastases from 30 patients who progressed on prior therapies (SU2C 20206-001). Patient outcomes including progression-free survival (PFS) and overall survival (OS) were observed.Results: We defined: (a) CDKN2A homozygous deletions that included the adjacent MTAP gene, only its' 3′ region, or excluded MTAP; (b) SMAD4 homozygous deletions that included ME2; (c) a pancreas-specific MYC super-enhancer region; (d) DNA repair-deficient genomes; and (e) copy number aberrations present in PDA patients with long-term (≥ 40 months) and short-term (≤ 12 months) survival after surgical resection.Conclusions: We provide a clinically relevant framework for genomic drivers of PDA and for advancing novel treatments.

AB - Background: Pancreatic ductal adenocarcinoma (PDA) is a lethal cancer with complex genomes and dense fibrotic stroma. This study was designed to identify clinically relevant somatic aberrations in pancreatic cancer genomes of patients with primary and metastatic disease enrolled and treated in two clinical trials.Methods: Tumour nuclei were flow sorted prior to whole genome copy number variant (CNV) analysis. Targeted or whole exome sequencing was performed on most samples. We profiled biopsies from 68 patients enrolled in two Stand Up to Cancer (SU2C)-sponsored clinical trials. These included 38 resected chemoradiation naïve tumours (SU2C 20206-003) and metastases from 30 patients who progressed on prior therapies (SU2C 20206-001). Patient outcomes including progression-free survival (PFS) and overall survival (OS) were observed.Results: We defined: (a) CDKN2A homozygous deletions that included the adjacent MTAP gene, only its' 3′ region, or excluded MTAP; (b) SMAD4 homozygous deletions that included ME2; (c) a pancreas-specific MYC super-enhancer region; (d) DNA repair-deficient genomes; and (e) copy number aberrations present in PDA patients with long-term (≥ 40 months) and short-term (≤ 12 months) survival after surgical resection.Conclusions: We provide a clinically relevant framework for genomic drivers of PDA and for advancing novel treatments.

KW - CNVs

KW - flow sorting

KW - focal amplicons

KW - homozygous deletions

KW - KRAS mutations

KW - pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=85027052008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027052008&partnerID=8YFLogxK

U2 - 10.1038/bjc.2017.209

DO - 10.1038/bjc.2017.209

M3 - Article

C2 - 28720843

AN - SCOPUS:85027052008

VL - 117

SP - 572

EP - 582

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -